MDACC Study No:2011-0520 ( NCT No: NCT01444716)
Title:Phase II Study of Ofatumumab as Front-line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)
Principal Investigator:Alessandra Ferrajoli
Treatment Agent:Ofatumumab
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if ofatumumab can help to
control CLL. The safety of this drug will also be studied.

Ofatumumab is designed to bind to the surface of the leukemia cells . This may
cause the leukemia cells to die.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Leukemia
Phase of Study:Phase II
Treatment Agents:Ofatumumab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:National Comprehensive Cancer Network
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Alessandra Ferrajoli
For Clinical Trial Enrollment:713-792-2063
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults